Prevalence of viral hepatitis (B and C) serological markers in healthy working population. 2013

José Luis Calleja-Panero, and Elba Llop-Herrera, and Montserrat Ruiz-Moraga, and Juan de-la-Revilla-Negro, and Eva Calvo-Bonacho, and Fernando Pons-Renedo, and José Luis Martínez-Porras, and Dolores Vallejo-Gutiérrez, and Carmen Arregui, and Luis Abreu-García

OBJECTIVE prevalence of viral hepatitis (B and C) changes geographically. Our aim was to determinate the prevalence of hepatitis B (HBV) and hepatitis C virus (HCV) serological markers in healthy working population and to describe the epidemiological characteristics associated to its presence. METHODS blood samples and epidemiological data of 5,017 healthy workers from Murcia and Madrid were recorded prospectively. RESULTS a total of 5,017 healthy volunteers participated. Mean age 39 ± 11 years, men predominance (73 %). Prevalence of serological markers of HCV and HBV was 0.6 % and 0.7 %. Age of patients with HCV antibody was significantly higher (43 + or - 9 years vs. 39 + or - 11 years; p = 0.03). We observed significant differences in liver test values (alanine aminotransferase [ALT] 64 ± 56 IU/L vs. 28 ± 20 IU/L; p < 0.001; aspartate aminotransferase [AST] (51 + or - 45 IU/L vs. 23 + or - 12 IU/L; p < 0.001) and in gamma-glutamyltransferase(GGT) value (104 + or - 122 IU/L vs. 37 + or - 46 IU/L; p < 0.001. The presence of HCV antibody was related significantly to previous transfusion (13 % vs. 5 %; p = 0.03), tattoos (29 % vs. 13 %; p < 0.01), intravenous drug addiction (13 % vs. 0.2 %; p < 0.001) and coexistence with people with positive HCV antibody (16 % vs. 4 %; p < 0.001). In HBV no differences in basal characteristics were observed with exception in AST values (29 + or - 15 IU/L vs. 23 + or - 12 IU/L; p < 0.01). Hepatitis B surface antigen (HBsAg) was related significantly to previous transfusion (15 % vs. 5 %; p < 0.01), tattoos (26 % vs. 14 %; p = 0.04) and coexistence with people with positive HBsAg (17 % vs. 4 %; p < 0.001). CONCLUSIONS Prevalence of serological markers in healthy working population is low. Risk factors for infection were previous transfusion and tattoos. Intravenous drug addiction was only a risk factor in HCV.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

José Luis Calleja-Panero, and Elba Llop-Herrera, and Montserrat Ruiz-Moraga, and Juan de-la-Revilla-Negro, and Eva Calvo-Bonacho, and Fernando Pons-Renedo, and José Luis Martínez-Porras, and Dolores Vallejo-Gutiérrez, and Carmen Arregui, and Luis Abreu-García
January 1987, Asia-Pacific journal of public health,
José Luis Calleja-Panero, and Elba Llop-Herrera, and Montserrat Ruiz-Moraga, and Juan de-la-Revilla-Negro, and Eva Calvo-Bonacho, and Fernando Pons-Renedo, and José Luis Martínez-Porras, and Dolores Vallejo-Gutiérrez, and Carmen Arregui, and Luis Abreu-García
January 1979, Archives roumaines de pathologie experimentales et de microbiologie,
José Luis Calleja-Panero, and Elba Llop-Herrera, and Montserrat Ruiz-Moraga, and Juan de-la-Revilla-Negro, and Eva Calvo-Bonacho, and Fernando Pons-Renedo, and José Luis Martínez-Porras, and Dolores Vallejo-Gutiérrez, and Carmen Arregui, and Luis Abreu-García
January 1994, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru,
José Luis Calleja-Panero, and Elba Llop-Herrera, and Montserrat Ruiz-Moraga, and Juan de-la-Revilla-Negro, and Eva Calvo-Bonacho, and Fernando Pons-Renedo, and José Luis Martínez-Porras, and Dolores Vallejo-Gutiérrez, and Carmen Arregui, and Luis Abreu-García
March 1992, Journal of clinical microbiology,
José Luis Calleja-Panero, and Elba Llop-Herrera, and Montserrat Ruiz-Moraga, and Juan de-la-Revilla-Negro, and Eva Calvo-Bonacho, and Fernando Pons-Renedo, and José Luis Martínez-Porras, and Dolores Vallejo-Gutiérrez, and Carmen Arregui, and Luis Abreu-García
March 1988, JPMA. The Journal of the Pakistan Medical Association,
José Luis Calleja-Panero, and Elba Llop-Herrera, and Montserrat Ruiz-Moraga, and Juan de-la-Revilla-Negro, and Eva Calvo-Bonacho, and Fernando Pons-Renedo, and José Luis Martínez-Porras, and Dolores Vallejo-Gutiérrez, and Carmen Arregui, and Luis Abreu-García
January 2012, Annals of hepatology,
José Luis Calleja-Panero, and Elba Llop-Herrera, and Montserrat Ruiz-Moraga, and Juan de-la-Revilla-Negro, and Eva Calvo-Bonacho, and Fernando Pons-Renedo, and José Luis Martínez-Porras, and Dolores Vallejo-Gutiérrez, and Carmen Arregui, and Luis Abreu-García
July 1990, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
José Luis Calleja-Panero, and Elba Llop-Herrera, and Montserrat Ruiz-Moraga, and Juan de-la-Revilla-Negro, and Eva Calvo-Bonacho, and Fernando Pons-Renedo, and José Luis Martínez-Porras, and Dolores Vallejo-Gutiérrez, and Carmen Arregui, and Luis Abreu-García
January 2003, Casopis lekaru ceskych,
José Luis Calleja-Panero, and Elba Llop-Herrera, and Montserrat Ruiz-Moraga, and Juan de-la-Revilla-Negro, and Eva Calvo-Bonacho, and Fernando Pons-Renedo, and José Luis Martínez-Porras, and Dolores Vallejo-Gutiérrez, and Carmen Arregui, and Luis Abreu-García
January 1993, Revista de gastroenterologia de Mexico,
José Luis Calleja-Panero, and Elba Llop-Herrera, and Montserrat Ruiz-Moraga, and Juan de-la-Revilla-Negro, and Eva Calvo-Bonacho, and Fernando Pons-Renedo, and José Luis Martínez-Porras, and Dolores Vallejo-Gutiérrez, and Carmen Arregui, and Luis Abreu-García
January 1993, Gut,
Copied contents to your clipboard!